RLAY vs. RXRX
RLAY (Relay Therapeutics, Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, RLAY returned -13.07%/yr vs -37.04%/yr for RXRX. At a 0.49 correlation, their price movements are largely independent.
Performance
RLAY vs. RXRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RLAY achieves a 110.76% return, which is significantly higher than RXRX's -18.34% return.
RLAY
- 1D
- -1.05%
- 1M
- 25.83%
- YTD
- 110.76%
- 6M
- 106.13%
- 1Y
- 446.93%
- 3Y*
- 13.79%
- 5Y*
- -13.07%
- 10Y*
- —
RXRX
- 1D
- 3.41%
- 1M
- 12.46%
- YTD
- -18.34%
- 6M
- -24.09%
- 1Y
- -35.27%
- 3Y*
- -22.98%
- 5Y*
- -37.04%
- 10Y*
- —
RLAY vs. RXRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RLAY Relay Therapeutics, Inc. | 110.76% | 105.34% | -62.58% | -26.31% | -51.35% | -8.95% |
RXRX Recursion Pharmaceuticals, Inc. | -18.34% | -39.50% | -31.44% | 27.89% | -54.99% | -42.90% |
Correlation
The correlation between RLAY and RXRX is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.48 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.50 |
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021 | 0.49 |
The correlation between RLAY and RXRX shifts across timeframes, from 0.34 (1 year) to 0.50 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
RLAY:
$3.21B
RXRX:
$1.77B
RLAY:
-$1.57
RXRX:
-$1.17
RLAY:
290.19
RXRX:
24.19
RLAY:
4.99
RXRX:
1.73
RLAY:
$10.68M
RXRX:
$66.29M
RLAY:
$6.33M
RXRX:
-$22.83M
RLAY:
-$285.68M
RXRX:
-$505.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RLAY vs. RXRX — Risk / Return Rank
RLAY
RXRX
RLAY vs. RXRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RLAY | RXRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +6.94 | ||
| Sortino ratioReturn per unit of downside risk | +5.65 | ||
| Omega ratioGain probability vs. loss probability | 1.62 | 0.96 | +0.67 |
| Calmar ratioReturn relative to maximum drawdown | 16.01 | -0.61 | +16.61 |
| Martin ratioReturn relative to average drawdown | 45.68 | -0.95 | +46.63 |
Loading charts...
Drawdowns
RLAY vs. RXRX - Drawdown Comparison
The maximum RLAY drawdown since its inception was -96.75%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for RLAY and RXRX.
Loading charts...
Drawdown Indicators
| RLAY | RXRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.75% | -93.13% | -3.62% |
Max Drawdown (1Y)Largest decline over 1 year | -28.15% | -58.17% | +30.02% |
Max Drawdown (3Y)Largest decline over 3 years | -84.78% | -82.09% | -2.69% |
Max Drawdown (5Y)Largest decline over 5 years | -94.74% | -93.13% | -1.61% |
Current DrawdownCurrent decline from peak | -71.02% | -91.92% | +20.90% |
Average DrawdownAverage peak-to-trough decline | -69.15% | -75.48% | +6.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.84% | 37.37% | -27.53% |
Volatility
RLAY vs. RXRX - Volatility Comparison
The current volatility for Relay Therapeutics, Inc. (RLAY) is 19.13%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 24.73%. This indicates that RLAY experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RLAY | RXRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.13% | 24.73% | -5.60% |
Volatility (6M)Calculated over the trailing 6-month period | 48.44% | 45.11% | +3.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.04% | 70.67% | -0.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.46% | 93.61% | -15.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 77.64% | 93.44% | -15.80% |
Dividends
RLAY vs. RXRX - Dividend Comparison
Neither RLAY nor RXRX has paid dividends to shareholders.
Financials
RLAY vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between Relay Therapeutics, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
RLAY and RXRX have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RXRX has higher volatility (24.73%) compared to RLAY (19.13%). In terms of maximum drawdown, RLAY dropped -96.75% vs RXRX's -93.13%.
RLAY currently has the higher Sharpe Ratio (6.44 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RLAY and RXRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer